• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Researchers Highlight Promise of AI in Diagnosing, Managing NAFLD


Sifting through large quantities of data using artificial intelligence (AI) could one day change how nonalcoholic fatty liver disease (NAFLD) is diagnosed, managed, and treated, according to a recent review.

Artificial intelligence (AI) and its subsets may play a key role in the coming years in the diagnosis and management of the growing problem of nonalcoholic fatty liver disease (NAFLD), according to a recent review.

In particular, AI and its subdisciplines of supervised and unsupervised machine learning and deep learning and deep neural networks could assist with patient identification, determination of disease severity, and drug development in order to close knowledge gaps by sifting through vast amounts of data, the authors said.

Multiple studies have already identified several ways in which these advances—if verified with larger randomized controlled trials—could improve patient outcomes.

Applying deep learning to electronic health records could identify high-risk patients and clinical predictors of disease with improved accuracy. In patients with more advanced disease, deep learning and deep neural networks could reduce interobserver variability among pathologists, and, since the current gold standard for diagnosis is a liver biopsy, avoid the need for invasive testing. Earlier, easier identification can also enable lifestyle modifications, which are key to slowing disease progression.

As an example, the authors highlighted one study that used machine learning to predict the presence of NAFLD in the general population with MRI imaging available in order to create a model that produced the NAFLD ridge score, which included 6 clinical characteristics (alanine aminotransferase, high-density lipoprotein cholesterol, triglyceride, hemoglobin A1c, white blood cell count, hypertension). In the training cohort, the area under the receiver operating characteristic curve was 0.87 and in the validation cohort it was 0.88.

In another study involving more than 10,000 patients, researchers used AI to identify triglycerides, alanine aminotransferase, gamma-glutamyltransferase, uric acid, and body mass index as the most effective predictive markers of NAFLD.

In stratifying severity in patients with NAFLD as well as nonalcoholic steatohepatitis and advanced fibrosis, the authors highlighted a research platform that was used to train a deep neural network with more than 20 layers and 8 million parameters from more than 600 liver biopsies. The machine learning models and the pathologist interpretations had strong agreement, which could pave the way in the future to improved work efficiency, increase uniformity, and speed processing.

As there are limited options for NAFLD drug therapy, the authors said, AI could identify patient response, particularly by taking into account their genomics and environmental exposures. AI could also be used to identify possible new drug targets or repurpose existing medications.


Aggarwal P, Alkhouri N. Artificial intelligence in nonalcoholic fatty liver disease: A new frontier in diagnosis and treatment. Clin Liver Dis. Published online August 5, 2021. doi:10.1002/cld.1071

Related Videos
dr sara horst
Mike Koroscik, MBA, MHA, Allina Health and the Allina Health Cancer Institute
Brian Mullen, PhD, head of innovation & product, The Clinic by Cleveland Clinic
Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland
dr sara horst
dr erin gillaspie
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Jennifer Sturgill, DO, Central Ohio Primary Care
Donna Fitzsimons
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy, Emory Winship Cancer Institute
Related Content
© 2023 MJH Life Sciences
All rights reserved.